Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients
| Autor: | L. S. Hermann, L. Ugander, P. Katzman, A. Nilsson, J. Kalén, I. Lager, O. Norrhamn, G. Sartor |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
business.industry Cholesterol Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Type 2 diabetes Overweight medicine.disease Placebo Metformin chemistry.chemical_compound Endocrinology High-density lipoprotein chemistry Internal medicine Low-density lipoprotein Internal Medicine medicine medicine.symptom business medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 3:428-434 |
| ISSN: | 1462-8902 |
| DOI: | 10.1046/j.1463-1326.2001.00160.x |
| Popis: | SUMMARY Aim To assess the adjunct effect of metformin to insulin in type 2 diabetes. Methods Obese and overweight type 2 diabetes patients treated with insulin for at least 1 year, and with poor glycaemic control (HbA1c > upper reference level + 2%), were included in a randomised, double-blind, placebo-controlled study. Patients were treated for 12 months with either metformin (850 mg b.i.d.) or placebo added to their usual insulin, which was stabilized during a 3-month placebo run-in period, but thereafter attempted to be unchanged. Results Thirty-seven patients were included. Two patients dropped out during run-in. There were no differences between the metformin (n = 16) and placebo (n = 19) group at baseline. Most patients received multiple insulin injections. Metabolic control was improved by addition of metformin. Mean change in HbA1c from baseline showed highly significant difference between groups at 3, 6, 9 and 12 months. Mean change (percentage units ± s.d.) at 12 months was −1.1 ± 0.7% vs. + 0.3 ± 0.8% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text